A Review on Conventional and Novel Topical Ocular Drug Delivery System

Mohamad Faeznudin Rozi; Awis Sukarni Mohmad Sabere

doi:10.31436/jop.v1i1.32

Authors

Mohamad Faeznudin Rozi Department of Pharmaceutical Chemistry, Kulliyyah of Pharmacy, International Islamic University Malaysia (IIUM), Jalan Sultan Ahmad Shah, 25200 Kuantan, Pahang, Malaysia
Awis Sukarni Mohmad Sabere Department of Pharmaceutical Chemistry, Kulliyyah of Pharmacy, International Islamic University Malaysia (IIUM), Jalan Sultan Ahmad Shah, 25200 Kuantan, Pahang, Malaysia

DOI:

https://doi.org/10.31436/jop.v1i1.32

Keywords:

drug delivery systems, ocular drug delivery, ophthalmic solutions

Abstract

Ocular drug delivery is a very challenging area for ophthalmologists and drug delivery scientists due to the structural and barrier complexity of the eye. Barriers such as different layers of cornea, sclera, conjunctival blood flow, and tear dilution limit the efficacy of drug delivery to the anterior part of the eye in addition to more barriers present to the posterior part. Due to these, scientists have designed and studied various delivery systems to increase drug delivery and treatment efficacy to the eye. Among conventional ocular drug delivery systems, ophthalmic solution or eye drop is widely used and preferred by consumers. Conventional dosage forms available in the market are emulsion, suspension, ointment and polymeric gels. Several ocular formulations such as nano-formulations, liposomes, ocular inserts, and ocular mini-tablets are also being widely studied as future treatments to improve ocular drug delivery and as an alternative to conventional drug delivery. This review intends to summarise several conventional and novel topical formulations for ocular drug delivery.

References

Aldrich, D. S., Bach, C. M., Brown, W., Chambers, W., Fleitman, J., Hunt, D., & Tin, G. W. (2013). Ophthalmic preparations. USP Council of Experts, 39(5).

Ali, Y., & Lehmussaari, K. (2006). Industrial perspective in ocular drug delivery. Advanced Drug Delivery Reviews, 58(11), 1258-1268.

Baranowski, P., Karolewicz, B., Gajda, M., & Pluta, J. (2014). Ophthalmic drug dosage forms: Characterisation and research methods. The Scientific World Journal, 2014, 14p.

Budai, L., Hajdú, M., Budai, M., Gróf, P., Béni,S., Noszál, B., Klebovich, I., & Antal, I. (2007). Gels and liposomes in optimized ocular drug delivery: Studies on ciprofloxacin formulations. International Journal of Pharmaceutics, 343(1-2), 34-40.

Cavalli, R., Gasco, M. R., Chetoni, P., Burgalassi, S., & Saettone, M. F. (2002). Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. International Journal of Pharmaceutics, 238(1-2), 241-245.

Chetoni, P., Burgalassi, S., Monti, D., Najarro, M., & Boldrini, E. (2007). Liposome-encapsulated mitomycin C for the reduction of corneal healing rate and ocular toxicity. Journal of Drug Delivery Science and Technology, 17(1), 43-48.

Cholkar, K., Patel, A., Dutt Vadlapudi, A., & K. Mitra, A. (2012). Novel Nanomicellar Formulation Approaches for Anterior and Posterior Segment Ocular Drug Delivery. Recent Patents on Nanomedicinee, 2(2), 82-95.

Civiale, C., Licciardi, M., Cavallaro, G., Giammona, G., & Mazzone, M. G. (2009). Polyhydroxyethylaspartamide-based micelles for ocular drug delivery. International Journal of Pharmaceutics, 378(1-2), 177-186.

De Campos, A. M., Diebold, Y., Carvalho, E. L. S., Sánchez, A., & Alonso, M. J. (2004). Chitosan nanoparticles as new ocular drug delivery systems: In vitro stability, in vivo fate, and cellular toxicity. Pharmaceutical Research, 21(5), 803-810.

Friedrich, S. W., Saville, B. A., Cheng, Y. L., & Rootman, D. S. (1996). Pharmacokinetic differences between ocular inserts and eyedrops. Journal of Ocular Pharmacology and Therapeutics, 21(1), 5-18.

Gan, L., Wang, J., Jiang, M., Bartlett, H., Ouyang, D., Eperjesi, F., Liu, J., & Gan, Y. (2013). Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discovery Today, 18(5-6), 290-297.

Gaudana, R., Jwala, J., Boddu, S. H. S., & Mitra, A. K. (2009). Recent perspectives in ocular drug delivery. Pharmaceutical Research, 26(5), 1197-1216.

Ghate, D., & Edelhauser, H. F. (2006). Ocular drug delivery. Expert Opinion on Drug Delivery, 3(2), 275–287.

Gurtler, F., & Gurny, R. (1995). Patent literature review of ophthalmic inserts. Drug Development and Industrial Pharmacy, 21(1), 1-18.

Habib, F. S., Fouad, E. A., & Fathalla, D. (2008). Liposomes as an ocular delivery system of fluconazole: In-vitro studies. Bulletin of Pharmaceutical Sciences, 88(8), 901-904.

Kaur, I. P., Singh, M., & Kanwar, M. (2000). Formulation and evaluation of ophthalmic preparations of acetazolamide. International Journal of Pharmaceutics, 199(2), 119-127.

Kinoshita, S., Awamura, S., Oshiden, K., Nakamichi, N., Suzuki, H., & Yokoi, N. (2012). Rebamipide (OPC-12759) in the treatment of dry eye: A randomized, double-masked, multicenter, placebo-controlled phase II study. Ophthalmology, 119(12), 2471-2478.

Kumar, K. P., Bhowmik, D., Harish, G., Duraivel, S., & Kumar, B. (2013). Ocular inserts: a novel controlled drug delivery system. The Pharma Innovation, 1(12), 1-16.

Kumari, A., Sharma, P. K., Garg, V. K., & Garg, G. (2010). Ocular inserts-Advancement in therapy of eye diseases. Journal of Advanced Pharmaceutical Technology and Research, 1(3), 291-296.

Liang, H., Brignole-Baudouin, F., Rabinovich-Guilatt, L., Mao, Z., Riancho, L., Faure, M. O., Warnet, J. M., Lambert, G. & Baudouin, C. (2008). Reduction of quaternary ammonium-induced ocular surface toxicity by emulsions: An in vivo study in rabbits. Molecular Vision, 14, 204-216.

Mehanna, M. M., Elmaradny, H. A., & Samaha, M. W. (2010). Mucoadhesive liposomes as ocular delivery system: Physical, microbiological, and in vivo assessment. Drug Development and Industrial Pharmacy, 36(1), 108-118. Monkhouse, S. (2007). Clinical Anatomy: A Core Text with Self-assessment. London, United Kingdom: Churchill Livingstone.

Motwani, S. K., Chopra, S., Talegaonkar, S., Kohli, K., Ahmad, F. J., & Khar, R. K. (2008). Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: Formulation, optimisation and in vitro characterisation. European Journal of Pharmaceutics and Biopharmaceutics, 68(3), 513-525.

Nishiyama, N., & Kataoka, K. (2006). Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacology and Therapeutics, 112(3), 630-648.

Pahuja, P., Arora, S., & Pawar, P. (2012). Ocular drug delivery system: A reference to natural polymers. Expert Opinion on Drug Delivery, 9(7), 837-861.

Patel, A., Cholkar, K., Agrahari, V., & Mitra, A. K. (2013). Ocular drug delivery systems: An overview. World Journal of Pharmacology, 2(2), 47–64.

Qiu, L., Zhang, J., Yan, M., Jin, Y., & Zhu, K. (2007). Reverse self-assemblies based on amphiphilic polyphosphazenes for encapsulation of water-soluble molecules. Nanotechnology, 18(47), 9p.

Ranch, K., Patel, H., Chavda, L., Koli, A., Maulvi, F., & Parikh, R. K. (2017). Development of in situ ophthalmic gel of dexamethasone sodium phosphate and chloramphenicol: A viable alternative to conventional eye drops. Journal of Applied Pharmaceutical Science, 7(3), 101-108.

Rathore, K. S. (2010). In-situ gelling ophthalmic drug delivery system: An overview. International Journal of Pharmacy and Pharmaceutical Sciences, 9(3), 237-248.

Rathore, K. S., & Nema, R. K. (2009). An Insight into Ophthalmic Drug Delivery System. International Journal of Pharmaceutical Sciences and Drug Research, 1(1), 1-5.

Remington, J. P. (2011). Remington: The Science and Practice of Pharmacy. Maryland, USA: Lippincot Williams & Wilkins.

Sahoo, S. K., Dilnawaz, F., & Krishnakumar, S. (2008). Nanotechnology in ocular drug delivery. Drug Discovery Today, 13(3-4), 144-151.

Sakurai, E., Ozeki, H., Kunou, N., & Ogura, Y. (2001). Effect of particle size of polymeric nanospheres on intravitreal kinetics. Ophthalmic Research, 33(1), 31-36.

Sasaki, H., Yamamura, K., Mukai, T., Nishida, K., Nakamura, J., Nakashima, M., & Ichikawa,M. (1999). Enhancement of ocular drug penetration. Critical Reviews in Therapeutic Drug Carrier Systems, 16(1), 85-146.

Scoper, S. V., Kabat, A. G., Owen, G. R., Stroman, D. W., Kabra, B. P., Faulkner, R., Kulshreshtha, A. K., Rusk, C., Bell, B., Jamison, T., Bernal-Perez, L. F., Brooks, A. C. &Nguyen, V. A. (2008). Ocular distribution, bactericidal activity and settling characteristics of TobraDex® ST ophthalmic suspension compared with TobraDex® ophthalmic suspension. Advances in Therapy, 25(2), 77-88.

Seyfoddin, A., Shaw, J., & Al-Kassas, R. (2010). Solid lipid nanoparticles for ocular drug delivery. Drug Delivery,17(7), 467-489.

Shaikh, R., Raj Singh, T. R., Garland, M. J., Woolfson, A. D., & Donnelly, R. F. (2011). Mucoadhesive drug delivery systems. Journal of Pharmacy & Bioallied Sciences, 3(1), 89–100.

Shen, Y., & Tu, J. (2007). Preparation and ocular pharmacokinetics of ganciclovir liposomes. AAPS Journal, 9(3), E371-E377.

Souza, J. G., Dias, K., Pereira, T. A., Bernardi, D. S., & Lopez, R. F. V. (2014). Topical delivery of ocular therapeutics: Carrier systems and physical methods. Journal of Pharmacy and Pharmacology, 66(4), 507-530.

Sultana, Y., Jain, R., Aqil, M., & Ali, A. (2006). Review of ocular drug delivery. Current Drug Delivery, 3(2), 207-217.

Torchilin, V. P. (2006). Micellar Nanocarriers: Pharmaceutical Perspectives. Pharmaceutical Research, 24(1), 1.